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Abstract
Background: With ageing of the HIV-infected population, long-term exposure to treatment, varying adherence,
emerging resistance and complications to therapies, effectiveness of Highly Active Antiretroviral Therapy (HAART)
needs to be monitored continuously at the population level. The German HIV-1 Seroconverter Cohort is a
multi-centre, open, long-term observational cohort including patients with a known or reliably estimated date of
HIV-infection –i.e. last negative and first positive HIV antibody test within a maximum three-year interval or
laboratory evidence of seroconversion. Our study aims to investigate survival improvements and changes in AIDS
risk over calendar periods in the German HIV-1 Seroconverter Cohort.
Methods: Retrospective (for the pre-1997 period) and prospective (since 1997) data from the German HIV-1
Seroconverter Cohort were used. Time from seroconversion to first AIDS-defining event over calendar periods was
analysed by using Cox models adjusting for age at seroconversion, sex, transmission groups and short HIV test
interval. Kaplan-Meier methods were used to determine expected survival (remaining AIDS-free) by calendar period.
Results: 2162 seroconverters with 8976 person-years of observation were included in our analysis (up to
31.12.2010). A total of 196 first AIDS–defining events were reported. Two periods –i.e. 1997–2000 and
2007-2010– were statistically associated with a reduction in the risk of AIDS, accounting for an overall reduction of
80%. Compared to1997-2000, hazard ratios were 2.6 (95%CI, 1.6-4.8; p = 0.000) in pre-1997 and 0.5 (95%CI, 0.3-0.8;
p = 0.007) in 2007–2010. Independent risk factor for AIDS progression was age at seroconversion (HR, 1.3 per
10 year-increase; p = 0.001).
Conclusion: HAART effectiveness has improved in the German HIV-1-Seroconverter Cohort. The risk to develop
AIDS decreased significantly in 1997–2000 and in 2007–2010. However, elderly may require particular monitoring in
view of their faster progression to AIDS.
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Background
Long-term observational studies with reliable HIV-1 sero-
conversion dates are a good tool to assess the effectiveness
of highly active antiretroviral therapy (HAART) at the
population level [1]. They use calendar period as a proxy
for actual HAART use to circumvent confounding by indi-
cation [2]. Just after the introduction of HAART in 1996,
such studies showed a protective effect of HAART on time
to acquired immunodeficiency syndrome (AIDS) [3-5].
Thereafter, continuous decrease on time to AIDS has been
reported, coincident with the widespread uptake of HAART
[6-8]. However, with ageing of the HIV-infected population,
long-term exposure to treatment, varying adherence, emer-
ging resistance and complications to therapies, there is a
need to monitor regularly the effectiveness of HAART at
the population level. Furthermore, the introduction of new
drugs may have contributed to slowing down the disease
progression in more recent times.
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In Germany, HIV surveillance is regulated by the
national Protection against Infection Act since 2001 [9].
Newly diagnosed HIV infections are reported to the
Robert Koch-Institute (RKI), the national institute for
diseases surveillance and control. However, in this
surveillance system, the date of HIV infection is often
unknown. To supplement the mandatory reporting sys-
tem, the RKI set up in 1997 the HIV-1 Seroconverter
study, which allows estimating the time of infection,
leading to a reliable determination of AIDS incidence,
risk factors for AIDS and time to therapy initiation.
This paper aims to present the results of the German
HIV-1 Seroconverter study, covering more than 13 years
of surveillance, in order to monitor at the population




The German HIV-1 Seroconverter study started in 1997
as a national multicenter observational cohort study
including HIV-infected persons for whom the date of
seroconversion is known or could reliably be estimated.
Study participants are recruited by more than 22 out-
patient clinical centres, 40 medical practices specialised
on HIV/AIDS and seven local health authorities all over
Germany, mainly in German metropoles. All HIV
infected patients aged 18 years or older (at the time of
study enrolment) are eligible to be included in the cohort
if their date of seroconversion can be reliably estimated,
either as acute or as documented seroconverters, which
has been described in detail elsewhere [10]. Briefly, acute
seroconverters included individuals with laboratory
evidence of seroconversion and those with an interval of
maximum three months between the last negative and
the first positive HIV-antibody test (mid-point between
the dates is used to estimate the time of infection).
Documented seroconverters included individuals with a
last negative and a first positive HIV-antibody test within
a maximum three-year interval (mid-point between the
dates is used to estimate the time of infection).
Data collection
On the basis of a baseline standardized paper-based
questionnaire, demographic (including sex, age, and HIV
exposure category), clinical (including CDC-status and
current therapy regimes) and laboratory data (including
viral load, CD4+ and CD8+ counts) are collected by phy-
sicians. Yearly follow-up questionnaires include CDC-
status and current therapy regimes. Questionnaires are
sent to the RKI where they are reviewed and integrated
in the HIV database, and checked for completeness and
plausibility. If data inconsistencies cannot be resolved,
the institutions are queried.
Statistical analyses
We analysed the time from seroconversion to AIDS via
Cox proportional hazard model, a method that allows for
late entry and inclusion of retrospectively ascertained
seroconversion [11]. Since the objective of these analyses
was to measure the effectiveness of HAART at the popu-
lation level, calendar year at risk was divided into five
calendar periods, according to the availability of new
anti-retroviral drugs in Germany: 1) the era before
HAART (pre-1997), 2) limited use of HAART and use of
two Nucleoside Reverse Transcriptase Inhibitors (NRTI)
with one Protease-Inhibitor (PI) or one Non-Nucleoside
Reverse Transcriptase Inhibitors (NNRTI) (1997–2000),
3) introduction of Lopinavir/Ritonavir as boosted PI in
one co formulation (2001–2004), 4) introduction of
secondary PI generation (2005–2006), and 5) the intro-
duction of Chemokine Coreceptor 5 (CCR5) antagonists
and integrase single strand transfer inhibitors (2007–
2010). Calendar period was included as a time-
dependent covariate so that each individual contributed
to the analyses with all time periods they had been at
risk. Time was always measured from date of serocon-
version so that comparisons across calendar periods were
only based on seroconverters who had been infected for
the same length of time. The second calendar period
(1997–2000) was used as reference period in the Cox
proportional hazard model.
Individuals were censored either by the day of the last
medical visit or by the date of the first AIDS-defining
event, defined in accordance with clinical criteria from
the 1993 Centers for Disease Control and Prevention
(CDC) case definition [12]. Individuals with pre-AIDS
mortality were censored as AIDS free at the moment of
death. Lost to follow up was defined as the number of
last medical visits in each calendar period. Due to a delay
of reporting, last medical visits in 2010 were not considered
as lost to follow up but as unknown status.
Adjustment was done for sex, HIV exposure category,
age at seroconversion and short HIV test interval
(already defined as acute seroconverters). HIV exposure
categories included, in the following order of priority:
injecting drug users (IDU), men who have sex with men
(MSM), heterosexuals, other (including blood transfusion
and occupational acquisition), and unknown. Among
heterosexuals, a new group including people originated
from high prevalence countries (HPC) was created. To
investigate whether the effects of these determinants
changed over time, we included interaction terms
between each determinant and the calendar periods at
risk. Interaction was tested using likelihood ratio tests.
Kaplan-Meier methods were used to determine the
expected survival probability (remaining AIDS-free) in
each calendar period and Log-rank tests for equality
of survivor functions. All p-values are two-sided, and a
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p-value of 0.05 or less was considered significant. All
data were analysed using STATA 11.0 (StataCorp LP,
College Station, TX, USA).
Ethics
The Seroconverter study was approved by the local
ethics committee of the Charité (University hospital) in
Berlin and reconfirmed in 2010. Informed consent was
obtained for each participant of the study.
Results
Study population
By the end of 2010, a total of 2162 eligible patients were
enrolled in the study and included in the analysis. Of
these, 214 patients were retrospectively included, namely
having a date of seroconversion before 1997. Both the
number of included patients and follow-up increased
largely after 2001, when the study was better established.
The overall median age at seroconversion was 33 years
(IQR: 27–39) without major changes over calendar periods
(Table 1). The main exposure category was MSM, repre-
senting 85.5% (1838/2162) of the study population and
resulting in a low proportion of women in the cohort (137/
2162; 6.3%). The MSM proportion increased as a propor-
tion of enrolled seroconverters in later calendar periods
(65.0% in pre-1997 to 87.6% in 2007–2010). The second
main HIV exposure category was heterosexual contacts,
representing 9.0% (195/2162) of the patients. IDU repre-
sented only 2.6% (55/2162) of the seroconverters and were
decreasingly enrolled over time. 1.5% (32/2,162) of the
patients originated from high prevalence countries. More
than 40% of the study population had a short HIV test
interval and this proportion increased over time. For those
including in the documented seroconverters (HIV test
interval bigger than 3 months), the HIV test interval was
between 3 and 12 months.
AIDS-defining events, incidence rate and survival
Over the 8906 person-years (PY) of follow up (median =
2.8 years; range 1 day – 23.9 years), 196 first AIDS-
defining events were reported, leading to an overall AIDS
incidence rate of 2.2 per 100 PY (95% CI, 1.9-2.5). The
AIDS incidence rate per 100 PY decreased significantly
from 6.9 in pre-1997 (95% CI, 4.9-9.6) to 2.6 (95% CI,
1.7-4.0) in 1997–2000, 1.9 (95% CI, 1.3-2.9) in 2001–
2004, 3.7 (95% CI, 2.8-5.0) in 2005–2006 and 1.3 (95%
CI, 1.1-1.7) in 2007–2010 (Table 1). Among the 196
reported AIDS-defining events, opportunistic infections
(139/196, 71%) were the most prevalent, followed by
Kaposi's sarcoma (21/196, 11%), lymphoma (15/196, 8%),
HIV encephalitis (11/196, 5%) and cachexia (10/196, 5%).
The proportion of patients developing AIDS within 2
and 10 years decreased significantly (p = 0.0001) from
14% and 50% in pre-1997 to 4% and 33% in 1997–2000,
respectively (Figure 1). The two following periods did
not show a decrease in the proportions of patients devel-
oping AIDS within 2 and 10 years in comparison to
1997–2000. In the last period (2007–2010), these pro-
portions further decreased significantly (p = 0.0129) to
4% and 11%, respectively.
Table 1 Description of the German HIV-1 Seroconverter Cohort by the end of 2010
Calendar year of seroconversion
Pre-1997 1997-2000 2001-2004 2005-2006 2007-2010 Overall
Sex, female, n (%) 32 (15) 13 (7.0) 32 (5.6) 29 (6.2) 31 (4.2) 137 (6.3)
Age at seroconversion, (year) [median (IQR)] 30 (26–38) 32 (27–36) 33 (27–38) 33 (28–40) 33 (27–40) 33 (27–39)
HIV exposure category [n (%)]
men who have sex with men 139 (65.0) 152 (82.6) 500 (88.2) 406 (87.7) 641 (87.6) 1838 (85.0)
Injecting drug users 32 (15.0) 5 (2.7) 10 (1.8) 5 (1.1) 3 (0.4) 55 (2.6)
heterosexuals 34 (15.9) 16 (8.7) 40 (7.1) 41 (8.8) 64 (8.8) 195 (9.0)
people from high endemic country 6 (2.8) 6 (3.2) 9 (1.6) 5 (1.1) 7 (1.0) 33 (1.5)
others* 0 (0) 2 (1.1) 2 (0.4) 1 (0.2) 4 (0.6) 9 (0.4)
unknown 3 (1.4) 3 (1.6) 6 (1.1) 7 (1.5) 13 (1.8) 32 (1.5)
Short HIV test interval †, n (%) 33 (15.4) 53 (28.7) 206 (36.3) 208 (44.7) 401 (54.9) 901 (41.7)
Seroconverters, n (Follow up{) 214 (520) 185 (837) 567 (1201) 465 (1259) 731 (5090) 2162 (8906)
AIDS events, n, (rate±) 36 (6.9) 22 (2.6) 23 (1.9) 47 (3.7) 68 (1.3) 196 (2.2)
Pre-AIDS mortality, n (rate±) NA 5 (0.6) 4 (0.3) 4 (0.3) 14 (0.3) 27 (0.3)
Lost to follow-up, n (rate±) 2 (0.4) 85 (10.2) 169 (14.1) 126 (10.0) 303 (10.5) 685 (10.2)
* Occupational and blood transfusion.
† Defined as ≤3 months between last negative and first positive HIV test, or with laboratory evidence of seroconversion.
{ Follow up in person-year.
± Rate calculation: number of events/100 person-years.
IQR: Interquartile range; NA: Not available.
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Pre-AIDS mortality and lost to follow-up
Death without AIDS, which accounted for 27 of the
cases, had a relatively stable rate over calendar periods
after 1997 (as this information was not retrospectively
collected for the pre-1997 period), from 0.6 per 100 PY
in 1997–2000 to 0.3 per 100 PY in the following periods.
The lost to follow up rate was also relatively stable over
the calendar periods, except for the pre-1997 period
where it was lower (0.4 per 100 PY) (Table 1).
Calendar periods and prognostic factors
In the multivariable model adjusted for sex, age at sero-
conversion, HIV exposure category and short HIV test
interval, two periods –i.e. 1997–2000 and 2007–2010–
were statistically associated with a reduction in the risk
of AIDS, accounting for an overall reduction of 80%.
Compared to 1997-2000, hazard ratios were 2.6 (95%CI,
1.6-4.8; p = 0.000) in pre-1997 and 0.5 (95%CI, 0.3-0.8;
p = 0.007) in 2007–2010 (Table 2). Both the 2001–2004
and 2005–2006 periods did not show significant differences
in the risk of AIDS compared to the 1997–2000
period, but only a slight non-significant increase in
2005–2006.
Older age at seroconversion was associated with an
increased risk of AIDS (HR, 1.3 per 10 year-increase;
p = 0.001). Compared to the group of MSM, the risks
among people originating from HPC and IDU were not
significantly increased, with HR of 2.3 (95%CI 1.0-5.3;
Figure 1 Proportion of AIDS free patients (with 95% Confident Interval) after HIV seroconversion over time, by calendar period, Germany.
Table 2 Adjusted Hazard Ratios of progression to first




Pre-1997 2.6 1.6 4.8 0.000
1997-2000 1.0 1.0 1.0 -
2001-2004 0.7 0.4 1.2 0.191
2005-2006 1.3 0.8 2.2 0.316
2007-2010 0.5 0.3 0.8 0.007
Sex, women 1.2 0.6 2.3 0.544
Age (per 10 years increase in age) 1.3 1.1 1.5 0.001
HIV exposure category
men who have sex with men 1.0 1.0 1.0 -
Injecting drug users 1.4 0.8 2.7 0.229
heterosexuals 0.8 0.4 1.5 0.479
people from high endemic country 2.3 1.0 5.3 0.053
others* 1.1 0.2 8.0 0.910
unknown 1.6 0.6 4.4 0.340
Short HIV test interval { 1.3 1.0 1.8 0.056
* Occupational and blood transfusion.
† adjusted for calendar period, sex, age at seroconversion, HIV exposure
category, short HIV test interval.
{ defined as ≤3 months between last negative and first positive HIV test, or
with laboratory evidence of seroconversion.
HR: Hazard Ratio; CI, confident interval.
Altmann et al. BMC Infectious Diseases 2012, 12:94 Page 4 of 8
http://www.biomedcentral.com/1471-2334/12/94
p= 0.053) and 1.4 (95%CI, 0.8-2.8; p = 0.229), respectively.
Heterosexual transmission had a similar risk as compared
with homosexual male transmission (HR, 0.8; 95% CI 0.4-
1.5; p = 0.479).
To investigate whether the prognostic effects of these
covariates had changed over time, we included interac-
tions between calendar period and each of the covariates
in the Cox model. To reduce model instability, we
collapsed the calendar periods to pre-1997, 1997–2006
and 2007–2010, and excluded 9 patients with occupa-
tional exposure and 36 with unknown exposure. There
was no evidence of a change over time in the effect of
age (p = 0.1287) although we noticed a decrease in the
HR from 1.6 to 1.0 over the calendar periods (Table 3).
There were no significant changes in the effect of sex
and short HIV test interval. Although HIV exposure cat-
egories did not change over time (p = 0.5575), the risk of
AIDS decreased less among IDU than for the other HIV
exposure categories over the calendar periods.
Therapy/time to therapy
While mono and dual NRTI therapy were mostly used
before 1997, main combinations of HAART included 2
NRTI/PI till 2001 and a mixed of 2 NRTI/PI and 2
NRTI/NNRTI after this date. While the proportion of PY
spent on antiretroviral therapy was 51% for the whole
cohort, this proportion changes over the calendar peri-
ods, from 13% in pre-1997 to 48%, 59%, 45% and 54% in
1997–2000, 2001–2004, 2005–2006 and 2007–2010,
respectively. The median time from seroconversion to
therapy initiation was 1.3 years [interquartile range
(IQR), 0.5-2.8 years]. The temporal trend of this median
showed first a decrease from 1.6 in pre-1997 to 0.8
and 0.4 years in 1997–2000 and 2001–2004 respectively,
followed by an increase to 1.4 and 1.9 years in 2005–
2006 and 2007–2010 respectively. More precisely, this
trend was confirmed when analysing proportions of
person-years spent on treatment over total follow-up
time, stratified by calendar period and categorised by the
proportion initiating treatment within 2 years, between 2
and 5 years, and more than 5 years (Figure 2). Whilst the
proportion of person-years on treatment within 2 years
after seroconversion decreased since 1997, the propor-
tion of patient-years on treatment 5 years and more after
seroconversion increased from 25% in pre-1997 to 82% in
2007–2010. The proportion initiating treatment between 2
and 5 years after seroconversion was more constant and
varied between 53 and 69% since 1997.
Discussion
By using the data from the German HIV-1 Seroconverter
Cohort, we estimated the risk of AIDS in calendar peri-
ods with different HAART regimens as well as during
mono and dual antiretroviral therapy (pre-1997). We
found an overall reduction of 80% in the risk of AIDS
over the calendar periods, which was not linear but
included two main drops, one after 1997 and one after
2007. This is the first study to our knowledge showing a
reduction in AIDS risk after 2007. However, these results
might be influenced by the fact that the study population
includes a large proportion of MSM who are more likely
to be closely monitored by HIV specialists and may
therefore not be representative of the entire German
population infected by HIV. A similar cohort study in
Spain reported significant reduction in the risk of
AIDS over calendar periods in comparison with the
pre-HAART era, but there were no differences be-
tween the calendar periods in the post-HAART era
[8]. However, the last observed calendar period was
2000–2003 and there were more IDU in the compos-
ition of this cohort than in our study. In another
study combining 22 cohorts of people living with
HIV-1 from Europe, Australia and Canada, the
authors showed an even bigger reduction in the risk
Table 3 Interactions between prognostic factors and calendar periods in the German HIV-1 Seroconverter Cohort, 2010
Calendar periods P-value for
interactionpre-1997 1997-2007 2007-2010
HR† 95% CI HR† 95% CI HR† 95% CI
Sex, female 1.0 0.2-4.6 1.7 0.8 – 3.7 0.7 0.1 – 4.5 0.6509
Age (per 10 years increase in age) 1.6 1.1-2.2 1.4 1.2 - 1.8 1.0 0.8 - 1.4 0.1287
HIV exposure category
men who have sex with men 1 1 1
Injecting drug users 0.8 0.3 - 2.6 1.9 0.9 – 4.1 1.4 0.2 – 11.1 0.5575
heterosexuals 0.2 0.04 - 1.4 1.1 0.5 - 2.4 0.5 0.1 - 2.1
people from high endemic country 2.7 0.6 – 12.7 2.1 0.7 - 7.0 1.6 0.2 – 13.8
Short HIV test interval* 1.4 1.0 – 1.9 1.1 0.7 - 1.8 1.7 1.0 – 2.8 0.3956
*defined as ≤3 months between last negative and first positive HIV test, or with laboratory evidence of seroconversion.
† To ease the interpretation we show all hazard ratios in comparison to the MSM risk of the respective calendar period.
HR: Hazard Ratio; CI, confident interval.
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of AIDS, with a relative risk of 0.46 and 0.13 after
1997 and after 2001, respectively [6].
Our results showed an overall increase in HAART up-
take, which likely parallels the decrease in AIDS risk.
These trends have also been seen in the UK, where the
proportion of patients being treated by antiretroviral
therapy increased from less than 2% in pre-1996 to 58%
in 2004–2006 [7]. The decrease in HAART uptake in
2005–2006 in our study, associated with an increase
in AIDS risk and AIDS incidence in the same period,
supports the hypothesis of this association between
HAART uptake and AIDS risk. Increasing HAART up-
take benefits could have been balanced by an increasing
prevalence of Transmitted Drug Resistance (TDR) over
the calendar periods. However, one previous study in
the same cohort of seroconverters indicated a stable
prevalence of TDR over the time [13]. Other factors
related to the improvements in drug quality, including
safety and galenic formulation easing intake, together
with increases in HIV-knowledge among health pro-
fessionals have probably also contributed to the de-
crease in AIDS risk.
We observed a trend towards initiating treatment later
following seroconversion in later calendar periods. This
could be explained by the different recommendations
in Germany since 1997. Following the Vancouver
Conference [14] and the increasing uptake of HAART,
the main attitude in Germany was to “hit hard and
early” [15]. In 2002, following the large proportion of
people with antiretroviral therapy side effects/toxicity,
the German AIDS Society recommended to start therapy
below a threshold of 200 CD4+ cells per μL [16]. This
recommendation might partially explain the slight
decrease in HAART uptake and consequently, the slight
increase in AIDS risk for the period 2005–2006 in our
study. In 2008, recommendations were revised to initiate
the antiretroviral therapy below a threshold of 350 CD4+
cells per μL [17]. Surprisingly, this last recommendation
was not associated with an increase, neither in the median
time to treatment initiation nor in the proportion of
people being treated less than 2 years and between 2 and
5 years after seroconversion. However, this last period was
associated with a decrease in AIDS risk, indicating that
factors other than time to treatment initiation may play a
more important role in disease progression.
The main determinant that affects disease progression
in our cohort was age at seroconversion. This factor,
together with duration of infection, was already known
to be a crucial determinant of HIV disease progression
in developed countries before the introduction of
HAART [5]. However, age disparities seem to diminish
over the calendar periods in our cohort, as already
shown in another study including 22 cohorts [6].
Our results did not show an effect of sex on AIDS risk.
This result contrasts with recent studies that reported a
slower disease progression among women than men
[8,18]. However, the number of women in our study
population was too small to detect any potential
differences.
Comparing disease progression rates between trans-
mission risk groups in our study was difficult, consider-
ing the large proportion of MSM compared to the other
transmission groups. However, the trend over the calen-
dar periods showed that IDU had a smaller reduction in
AIDS risk as compared with the others risk groups. This
result is supported by Porter et al., reporting a smaller
reduction in AIDS risk in the post- HAART era among
IDU [6]. However, other causes of mortality, such as
hepatitis C, could confound this result. People from high
HIV prevalence countries had at higher, although non-
significant risk for progression to AIDS. Furthermore,
the risk seems to decrease with the calendar periods.
This result should reflect a heterogeneous population
and be interpreted with caution because of the small
number of people in this group. Nevertheless, access to
health services, health insurance status, poor adherence
to treatment [19] and other co-morbidities could have
played a role and may require special attention for this
group.
The presence of seroconversion illness, typically char-
acterized by “flu-like” symptoms, has been reported to
be associated with a more rapid disease progression
[20,21]. In order to avoid recall bias, short HIV test
interval has been reported to be a good proxy for the
presence of seroconversion illness [21]. In our study,
short HIV test interval factor showed a slight effect,
which appears to increase over time. However, this result
depends on the quality of the tests used and on the time
interval chosen to define “a short test interval”.
Figure 2 Proportion of person-year (PY) under therapy over the
total PY follow up from seroconversion, stratified by time from
seroconversion and calendar period, Germany.
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This study’s principal strength is its good quality
data on date of seroconversion, permitting reliable
approximation of AIDS incidence and risk. This study
also has the advantage of providing data for more
than 13 years of prospective follow-up from different
settings, representing roughly 10% of all new HIV
diagnoses reported to the national HIV surveillance
since 2004. However, some limitations have to be
raised. First, the data for the pre-1997 period are
retrospective and may not be as reliable as the data
from the prospective period. Patients in this period
were included regardless of their AIDS outcome; a
survivorship bias might have been introduced as
patients have to sign an informed consent at study
entry. Regarding the pre-AIDS mortality, this bias
might have been limited as the pre-AIDS mortality
rates were relatively stable and at a very low level
during the prospective periods. Regarding the lost to
follow up, rates were relatively stable over the time
periods but were at a high level. If lost to follow up
subjects have a more rapid progression, the pre-1997
period in our study might underestimate the risk of
AIDS in comparison to the other periods but our
results remain conservative to this regard. Alterna-
tively, we might have overestimate the first decrease
in the AIDS risk if lost to follow up subjects have a
slower disease progression. Considering only the peri-
ods after 1997, a bias might have been introduced if
lost of follow up subjects differ between the periods.
Further analyses (e.g. competing risk analysis) should
be performed to better answer that issue. Another
issue is that women are largely underrepresented in
this study (6.2%) in comparison with the national
reporting system, in which women accounted for as
many as 20% of all new diagnoses between 1997 and
2010. This proportion does not allow us to analyze
the effects of sex and HIV transmission categories
with enough power. Finally, we assumed continuous
HAART intake after treatment initiation. This limita-
tion might be important for the interpretation of the
proportion of people being treated by calendar period.
However, this does not change the interpretation of
the effectiveness over time. The treatment was consid-
ered to be HAART (i.e., three or more drugs that are
from two or more classes, or that contain abacavir) in
every calendar period from 1997 onwards, even if this
might not be the case for one or two percent.
Conclusions
HAART effectiveness has improved in the German HIV-1-
Seroconverter Cohort. After a main reduction in the risk of
AIDS in 1997–2000, a second significant decrease occurred
in 2007–2010. However, elderly may require particular
monitoring in view of their faster progression to AIDS.
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